Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

32.29 -0.21 (-0.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 822,577
Open 32.50
Bid (Size) 32.00 (1)
Ask (Size) 34.95 (17)
Prev. Close 32.50
Today's Range 31.75 - 32.66
52wk Range 26.47 - 41.61
Shares Outstanding 57,031,297
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Top Affordable Growth Stock
Harmony Biosciences (HRMY) exemplifies GARP investing with strong EPS growth, a low P/E ratio, and robust profitability in the rare neurology sector. 
Via Chartmill
Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress
From Harmony Biosciences Holdings, Inc.
Via Business Wire

Performance

YTD
-7.3%
-7.3%
1 Month
-11.3%
-11.3%
3 Month
-1.9%
-1.9%
6 Month
-5.9%
-5.9%
1 Year
-16.7%
-16.7%

More News

Read More
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Opportunity
Via Chartmill
Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Earnings Scheduled For August 5, 2025
Via Benzinga
Where Harmony Biosciences Hldgs Stands With Analysts
Via Benzinga
Harmony Biosciences Holdings (NASDAQ:HRMY): A Prime Affordable Growth Stock with Strong Fundamentals
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY): A Strong Growth Stock with Promising Technical Setup
Via Chartmill
Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Opportunity with Strong Fundamentals and Growth Potential
Via Chartmill
Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Growth Stock with Attractive Valuation
Via Chartmill
Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series
From Harmony Biosciences
Via Business Wire
6 Analysts Assess Harmony Biosciences Hldgs: What You Need To Know
Via Benzinga
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
Via Investor's Business Daily
Topics Intellectual Property
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) – An Undervalued Stock with Strong Fundamentals
Via Chartmill
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) - A Strong Candidate for Affordable Growth Investors
Via Chartmill
Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Holdings (NASDAQ:HRMY) – A Potentially Undervalued Stock in the Pharmaceutical Sector
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Growth Stock at a Reasonable Valuation
Via Chartmill
Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Holdings ([NASDAQ:HRMY](https://www.chartmill.com/stock/quote/HRMY/profile)) – A Strong Growth Stock with Technical Breakout Potential
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) – A Potentially Undervalued Stock with Strong Fundamentals
Via Chartmill
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) - A Strong Candidate for Affordable Growth Investors
Via Chartmill

Frequently Asked Questions

Is Harmony Biosciences Holdings, Inc. - Common Stock publicly traded?
Yes, Harmony Biosciences Holdings, Inc. - Common Stock is publicly traded.
What exchange does Harmony Biosciences Holdings, Inc. - Common Stock trade on?
Harmony Biosciences Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Harmony Biosciences Holdings, Inc. - Common Stock?
The ticker symbol for Harmony Biosciences Holdings, Inc. - Common Stock is HRMY on the Nasdaq Stock Market
What is the current price of Harmony Biosciences Holdings, Inc. - Common Stock?
The current price of Harmony Biosciences Holdings, Inc. - Common Stock is 32.29
When was Harmony Biosciences Holdings, Inc. - Common Stock last traded?
The last trade of Harmony Biosciences Holdings, Inc. - Common Stock was at 09/16/25 04:00 PM ET
What is the market capitalization of Harmony Biosciences Holdings, Inc. - Common Stock?
The market capitalization of Harmony Biosciences Holdings, Inc. - Common Stock is 1.84B
How many shares of Harmony Biosciences Holdings, Inc. - Common Stock are outstanding?
Harmony Biosciences Holdings, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.